ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

evorpacept

Also written as “Evorpacept (ALX148)” and “Evorpacept”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Breast Neoplasms · Stomach Neoplasms · Neoplasm Metastasis · Urinary Bladder Neoplasms, led by 2 companies.

Drug pageALX148: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 27, 20219 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ALX Oncologyits history only83 open or runningphase 3since Jul 27, 2021Dec 15, 2016Dec 2027phase 2 · NCT07007559
Jazz Pharmaceuticals10 open or runningphase 2since Aug 23, 2021Aug 23, 2021none ahead

Also a collaborator on its studies: Eli Lilly and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jazz Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 23, 2021First study: phase 2 study in HER2-expressing CancersFirst studyNCT05027139 · 52 enrolled · United States
  2. Jan 25, 2022Named evorpaceptINNProposed as its International Nonproprietary Name in WHO's List 126

TargetBeta

CD47 →read by rule
“Leukocyte surface antigen CD47 inhibitor”ChEMBL 37, by rule

Other programs on CD47

ProgramCompanyFurthest phaseStudies
ligufalimabruleAkesophase 311
Anti-PD-1/CD47 Fusion Protein HX009rulehangzhou-hanx-biopharmaceuticals-ltdphase 25
CD47 Antagonist AUR103 CalciumruleDr. Reddy's Laboratoriesphase 22
1200mg of tqb2928 injectionSino Biopharmaceuticalphase 12

Studies

The one study Jazz Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05027139HER2-expressing Cancers · United States2CompletedAug 29, 202552

How it is read

Names in the registry

  • “evorpacept”, 4 entries
  • “Evorpacept (ALX148)”, 3 entries
  • “Evorpacept”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.